A placebo-controlled, dose-finding, phase II trial testing the efficacy and safety of BG00012, an oral formulation ... with relapsing–remitting multiple sclerosis (MS). Compared with placebo ...
Hormonal changes at puberty may trigger disease activity, but DMTs reduced the risk, indicating more aggressive treatment may be warranted.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback